Floatz logo

Bxcl501

Schizophreniform Disorders

BioXcel Therapeutics IncPhase 4 / ApprovedActive
A
80/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Schizophreniform Disorders cohort.

Asset / SponsorPhaseRating
Raloxifene
Iris Sommer
Phase 4A
Olanzapine
Alkermes, Inc.
Phase 4A
N-Acetyl-L-Cysteine
University of Maryland, Baltimore
Phase 4BBB
Risperdal
Northwell Health
Phase 4BBB
SIMVASTATIN
Iris Sommer
Phase 3BB

View all 41 →

Same molecule, other indications

Bxcl501 is also rated in:

Pain, ChronicDormant
A
Indicative ·
80 / 100
View asset →
Agitation,PsychomotorDormant
A
Indicative ·
80 / 100
View asset →
schizoaffective disorderDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →